Fed Ghali, MD

Biomarkers

• Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy StudyGhali F, Vakar-Lopez F, Roudier M, Garcia J, Arora S, Cheng H, Schweizer M, Haffner M, Lee J, Yu E, Grivas P, Montgomery B, Hsieh A, Wright J, Lam H. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. Clinical Genitourinary Cancer 2023, 21: 669-678. PMID: 37344281, PMCID: PMC10674028, DOI: 10.1016/j.clgc.2023.05.014.
• The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and OpportunitiesGhali F, Wright J, Grivas P. The Pursuit of Intravesical and Systemic Therapies in Non–muscle-invasive Bladder Cancer: Challenges and Opportunities. European Urology Oncology 2023, 6: 321-322. PMID: 37045706, DOI: 10.1016/j.euo.2023.03.006.
• Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level AnalysisGhali F, Zhao Y, Patel D, Jewell T, Yu E, Grivas P, Montgomery R, Gore J, Etzioni R, Wright J. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis. European Urology Open Science 2022, 47: 58-64. PMID: 36601043, PMCID: PMC9806712, DOI: 10.1016/j.euros.2022.11.003.
• External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter studyRaheem A, Landi I, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, De Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Santok G, Tadifa J, Syling J, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Bazan A, Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Ghaith A, Hagras A, Ghoneem A, Eissa A, Alqahtani A, Rumaih A, Alwahabi A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study. International Journal Of Urology 2022, 30: 308-317. PMID: 36478459, DOI: 10.1111/iju.15108.
• PD15-07 RENAL CELL CARCINOMA PARANEOPLASTIC SYNDROME SCORE: CONSTRUCTION AND VALIDATIONSoliman S, Noyes S, Meagher M, Rosenberg J, Leonard A, Hakimi K, Yuan J, Walia A, Saidian A, Ghali F, Javier-Desloges J, Patel D, McKay R, Derweesh I, Lane B. PD15-07 RENAL CELL CARCINOMA PARANEOPLASTIC SYNDROME SCORE: CONSTRUCTION AND VALIDATION. Journal Of Urology 2022, 207: e264. DOI: 10.1097/ju.0000000000002547.07.
• PD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS?Ghali F, Roudier M, Vakar-Lopez F, Garcia J, Wang Y, Ha G, Grivas P, Lee J, Yu E, Montgomery B, Hsieh A, Wright J, Lam H. PD53-09 ANTIBODY DRUG CONJUGATES AND VARIANT HISTOLOGY MUSCLE-INVASIVE BLADDER CANCER: ARE THE TARGETS PRESENT IN PRIMARY AND/OR METASTATIC TUMORS? Journal Of Urology 2022, 207: e913. DOI: 10.1097/ju.0000000000002630.09.
• MP56-20 SURROGATE ENDPOINTS AS PREDICTORS OF SURVIVAL IN METASTATIC UROTHELIAL CANCER TRIALSGhali F, Patel D, Jewell T, Gore J, Wright J. MP56-20 SURROGATE ENDPOINTS AS PREDICTORS OF SURVIVAL IN METASTATIC UROTHELIAL CANCER TRIALS. Journal Of Urology 2022, 207: e980. DOI: 10.1097/ju.0000000000002639.20.
• Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder CancerMiron B, Hawley J, Geynisman D, Mouw K, Sfakianos J, Weg E, Ghali F, Wright J, Grivas P, Khaki A. Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. Advances In Oncology 2022, 2: 213-225. DOI: 10.1016/j.yao.2022.02.007.
• Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC RegistryMeagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.
• Techniques of robotic assisted partial nephrectomy with renal vein tumor thrombectomy and reconstruction: UCSD experiencePatel D, Ghali F, Greear G, Holst D, Derweesh I. Techniques of robotic assisted partial nephrectomy with renal vein tumor thrombectomy and reconstruction: UCSD experience. Urology Video Journal 2022, 13: 100124. DOI: 10.1016/j.urolvj.2022.100124.
• Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis.Saidian A, Walia A, Patil D, Saito K, Patel D, Nguyen M, Chakoumakos M, Ghali F, Narasimhan R, Perry J, Meagher M, Yasuda Y, Fujii Y, Master V. Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis. Journal Of Clinical Oncology 2022, 40: 325-325. DOI: 10.1200/jco.2022.40.6_suppl.325.
• Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.
• Disparities in Telemedicine Utilization for Urology Patients During the COVID-19 PandemicJavier-DesLoges J, Meagher M, Soliman S, Yuan J, Hakimi K, Ghali F, Nalawade V, Patel DN, Monga M, Murphy JD, Derweesh I. Disparities in Telemedicine Utilization for Urology Patients During the COVID-19 Pandemic. Urology 2022, 163: 76-80. PMID: 34979219, PMCID: PMC8719918, DOI: 10.1016/j.urology.2021.11.037.
• Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patientsJavier-DesLoges JF, Meagher MF, Walia A, Nguyen MV, Perry JM, Narasimhan RS, Hakimi K, Soliman S, Yuan J, Chakoumakos MA, Ghali F, Patel DN, Wan F, Murphy JD, Derweesh IH. Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients. Urologic Oncology Seminars And Original Investigations 2021, 39: 837.e1-837.e7. PMID: 34580026, DOI: 10.1016/j.urolonc.2021.08.021.
• Re: Association of Black Race with Prostate Cancer–specific and Other-cause MortalityGhali F, Kane C. Re: Association of Black Race with Prostate Cancer–specific and Other-cause Mortality. European Urology 2021, 80: 758-759. PMID: 34535345, DOI: 10.1016/j.eururo.2021.09.004.
• MP26-16 PERFORMANCE OF PROMPT-PROSTATE GENETIC SCORE IN A JAPANESE COHORTNguyen V, Akamatsu S, Ghali F, Walia A, Terada N, Nakagawa H, Ogawa O, Kader A. MP26-16 PERFORMANCE OF PROMPT-PROSTATE GENETIC SCORE IN A JAPANESE COHORT. Journal Of Urology 2021, 206: e469-e469. DOI: 10.1097/ju.0000000000002023.16.
• MP42-17 ASSOCIATION OF TUMOR HISTOLOGY ON IMPACT OF LYMPH NODE DISSECTION ON SURVIVAL IN T2-T3 RENAL CELL CARCINOMA: ANALYSIS OF THE NATIONAL CANCER DATABASEGhali F, Cedars B, Patel D, Javier-Desloges J, Meagher M, Yuan J, Hakimi K, Soliman S, Patel S, Ballon-Landa E, Murphy J, Derweesh I. MP42-17 ASSOCIATION OF TUMOR HISTOLOGY ON IMPACT OF LYMPH NODE DISSECTION ON SURVIVAL IN T2-T3 RENAL CELL CARCINOMA: ANALYSIS OF THE NATIONAL CANCER DATABASE. Journal Of Urology 2021, 206: e778-e779. DOI: 10.1097/ju.0000000000002063.17.
• MP45-05 IMPACT OF ELEVATED C-REACTIVE PROTEIN ON SURVIVAL OUTCOMES IN SMALL RENAL MASSES: ANALYSIS OF THE INMARC REGISTRYMeagher M, Patil D, Saito K, Patel D, Javier-Desloges J, Ghali F, Hakimi K, Soliman S, Yuan J, Wan F, Fujii Y, Master V, Derweesh I. MP45-05 IMPACT OF ELEVATED C-REACTIVE PROTEIN ON SURVIVAL OUTCOMES IN SMALL RENAL MASSES: ANALYSIS OF THE INMARC REGISTRY. Journal Of Urology 2021, 206: e804-e804. DOI: 10.1097/ju.0000000000002066.05.
• MP45-12 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT ON INSURANCE STATUS, CANCER STAGE, AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMAJavier-DesLoges J, Hakimi K, Yuan J, Soliman S, Meagher M, Ghali F, Nawalade V, Patel D, Murphy J, Jolla, CA L, Kim S, Derweesh I. MP45-12 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT ON INSURANCE STATUS, CANCER STAGE, AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA. Journal Of Urology 2021, 206: e807-e808. DOI: 10.1097/ju.0000000000002066.12.
• V11-07 TECHNIQUES OF ROBOTIC ASSISTED PARTIAL NEPHRECTOMY WITH RENAL VEIN TUMOR THROMBECTOMY AND RECONSTRUCTION: UCSD EXPERIENCEPatel D, Holdst D, Greear G, Ghali F, Javier-DesLoges J, Patel S, Derweesh I. V11-07 TECHNIQUES OF ROBOTIC ASSISTED PARTIAL NEPHRECTOMY WITH RENAL VEIN TUMOR THROMBECTOMY AND RECONSTRUCTION: UCSD EXPERIENCE. Journal Of Urology 2021, 206: e859-e860. DOI: 10.1097/ju.0000000000002073.07.
• MP66-15 PATIENT-CENTRIC 3 DIMENSIONAL-BIOSYSTEMS FOR DEVELOPING PERSONALIZED IMMUNOTHERAPY FOR PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMALee S, Muldong M, Hsu J, Ghali F, Kang S, Kader A, Salmasi A, Jamieson C. MP66-15 PATIENT-CENTRIC 3 DIMENSIONAL-BIOSYSTEMS FOR DEVELOPING PERSONALIZED IMMUNOTHERAPY FOR PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA. Journal Of Urology 2021, 206: e1135-e1135. DOI: 10.1097/ju.0000000000002106.15.
• Warm ischemia time length during on-clamp partial nephrectomy: dose it really matter?Abdel Raheem A, Alowidah I, Capitanio U, Montorsi F, Larcher A, Derweesh I, Ghali F, Mottrie A, Mazzone E, DE Naeyer G, Campi R, Sessa F, Carini M, Minervini A, Raman J, Rjepaj C, Kriegmair M, Autorino R, Veccia A, Mir M, Claps F, Choi Y, Ham W, Tadifa J, Santok G, Furlan M, Simeone C, Bada M, Celia A, Carrión D, Aguilera Bazan A, Ballesteros Ruiz C, Malki M, Barber N, Hussain M, Micali S, Puliatti S, Alwahabi A, Alqahtani A, Rumaih A, Ghaith A, Ghoneem A, Hagras A, Eissa A, Alenzi M, Pavan N, Traunero F, Antonelli A, Porcaro A, Illiano E, Costantini E, Rha K. Warm ischemia time length during on-clamp partial nephrectomy: dose it really matter? Minerva Urologica E Nefrologica 2021, 74: 194-202. PMID: 34308610, DOI: 10.23736/s2724-6051.21.04466-9.
• Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care ActJavier-DesLoges JF, Yuan J, Soliman S, Hakimi K, Meagher MF, Ghali F, Hsiang W, Patel DN, Kim SP, Murphy JD, Parsons JK, Derweesh IH. Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act. JAMA Network Open 2021, 4: e2116267. PMID: 34269808, PMCID: PMC8285737, DOI: 10.1001/jamanetworkopen.2021.16267.
• P0614 Construction and validation of a standardized paraneoplastic syndrome for renal cell carcinomaSoliman S, Meagher M, Hakimi K, Yuan J, Wan F, Ghali F, Javier-Desloges J, Patel D, Derweesh I. P0614 Construction and validation of a standardized paraneoplastic syndrome for renal cell carcinoma. European Urology 2021, 79: s841-s842. DOI: 10.1016/s0302-2838(21)00991-x.
• The association between the Affordable Care Act on insurance status, cancer stage, and overall survival in patients with renal cell carcinoma.Javier-Desloges J, Yuan J, Soliman S, Hakimi K, Meagher M, Ghali F, Hsiang W, Patel D, Murphy J, Kim S, Derweesh I. The association between the Affordable Care Act on insurance status, cancer stage, and overall survival in patients with renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 281-281. DOI: 10.1200/jco.2021.39.6_suppl.281.
• A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group)Wu Z, Chen Q, Djaladat H, Minervini A, Uzzo R, Sundaram C, Rha K, Gonzalgo M, Mehrazin R, Mazzone E, Marcus J, Danno A, Porter J, Asghar A, Ghali F, Guruli G, Douglawi A, Cacciamani G, Ghoreifi A, Simone G, Margulis V, Ferro M, Tellini R, Mari A, Srivastava A, Steward J, Al-Qathani A, Al-Mujalhem A, Bhattu A, Mottrie A, Abdollah F, Eun D, Derweesh I, Veccia A, Autorino R, Wang L. A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group). European Urology Focus 2021, 8: 173-181. PMID: 33549537, DOI: 10.1016/j.euf.2021.01.014.
• Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer DatabasePatel DN, Ghali F, Meagher MF, Javier-Desloges J, Patel SH, Soliman S, Hakimi K, Yuan J, Murphy J, Derweesh IH. Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database. Urologic Oncology Seminars And Original Investigations 2020, 39: 79.e1-79.e8. PMID: 33160847, DOI: 10.1016/j.urolonc.2020.10.015.
• Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapyGhali F, Daly W, Hansen M, Hayn M, Sammon J, Beaule L, Sarkar R, Murphy J, Kader A, Derweesh I, Rose B, Ryan S. Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy. Urologic Oncology Seminars And Original Investigations 2020, 39: 130.e1-130.e7. PMID: 33121914, DOI: 10.1016/j.urolonc.2020.08.035.
• SC215 Oncologic outcomes after robot-assisted partial nephrectomy in the iron study: results from a large, global, multicentric analysis of patients with clinically localized kidney cancerRosiello G, Minervini A, Mari A, Bensalah K, Khene Z, Schiavina R, Bianchi L, Brunocilla E, Mottrie A, De Naeyer G, Antonelli A, Furlan M, Simeone C, Rha K, Almujalhem A, Derweesh I, Bradshaw A, Ghali F, Kaouk J, Sawczyn G, Bertolo R, Capitanio U, Montorsi F, Larcher A. SC215 Oncologic outcomes after robot-assisted partial nephrectomy in the iron study: results from a large, global, multicentric analysis of patients with clinically localized kidney cancer. European Urology Open Science 2020, 20: s129-s130. DOI: 10.1016/s2666-1683(20)35537-3.
• Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer DatabaseRyan S, Patel D, Ghali F, Patel S, Sarkar R, Yim K, Eldefrawy A, Cotta B, Bradshaw A, Meagher M, Hamilton Z, Murphy J, Derweesh I. Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database. Minerva Urologica E Nefrologica 2020, 73: 233-244. PMID: 32748614, DOI: 10.23736/s2724-6051.20.03728-5.
• 97 Comparative analysis of functional outcomes of open and minimally invasive partial nephrectomy stratified by tumor complexity: A multi-center studyGhali F, Patel D, Patel S, Rha K, Raheem A, Fayez A, Santok G, Tadifa J, Campi R, Minervini A, Sessa F, Alowidah I, Micali S, Kriegmair M, Mir M, Raman J, Riepai J, Ballesteros C, Autorino R, Veccia A, Capitanio U, Antonelli A, Furlan M, Simeone C, Derweesh I. 97 Comparative analysis of functional outcomes of open and minimally invasive partial nephrectomy stratified by tumor complexity: A multi-center study. European Urology Open Science 2020, 19: e230-e231. DOI: 10.1016/s2666-1683(20)32705-1.
• 101 Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter studyDutt R, Meagher M, Patil D, Saito K, Patel D, Ghali F, Keiner C, Miller N, Bradshaw A, Wan F, Yasuda Y, Fujii Y, Master V, Derweesh I. 101 Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study. European Urology Open Science 2020, 19: e236-e237. DOI: 10.1016/s2666-1683(20)32709-9.
• 161 Safety profile of robotic vs. laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the Robotic Surgery for Upper Tract Urothelial Cancer Study (ROBUUST) collaborative groupVeccia A, Steward J, Derweesh I, Margulis V, Uzzo R, Abdollah F, Minervini A, Cacciamani G, Mottrie A, Simone G, Rha K, Eun D, Mehrazin R, Gonzalgo M, Ghali F, Meng X, Srivastava A, Jamil M, Tellini R, Aron M, Mazzone E, Al-Qathani A, Asghar A, Sundaram C, Autorino R. 161 Safety profile of robotic vs. laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the Robotic Surgery for Upper Tract Urothelial Cancer Study (ROBUUST) collaborative group. European Urology Open Science 2020, 19: e316-e318. DOI: 10.1016/s2666-1683(20)32769-5.
• 164 Robotic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) collaborative groupVeccia A, Steward J, Derweesh I, Margulis V, Uzzo R, Abdollah F, Minervini A, Cacciamani G, Mottrie A, Simone G, Rha K, Eun D, Mehrazin R, Gonzalgo M, Ghali F, Meng X, Srivastava A, Jamil M, Riccardo T, Aron M, Mazzone E, Al-Qathani A, Asghar A, Sundaram C, Autorino R. 164 Robotic radical nephroureterectomy for upper tract urothelial carcinoma: Data from the ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) collaborative group. European Urology Open Science 2020, 19: e322-e324. DOI: 10.1016/s2666-1683(20)32772-5.
• 477 Utilization of renal mass biopsy in patients with localized renal cell carcinomaPatel D, Ghali F, Patel S, Miller N, Bradshaw A, Meagher M, Murphy J, Derweesh I. 477 Utilization of renal mass biopsy in patients with localized renal cell carcinoma. European Urology Open Science 2020, 19: e745-e746. DOI: 10.1016/s2666-1683(20)33080-9.
• 601 The impact of delay in time to surgery on outcomes of localized renal cell carcinoma: Analysis based on tumor sizePatel D, Ghali F, Meagher M, Bradshaw A, Patel S, Dutt R, Miller N, Keiner C, Cotta B, Murphy J, Derweesh I. 601 The impact of delay in time to surgery on outcomes of localized renal cell carcinoma: Analysis based on tumor size. European Urology Open Science 2020, 19: e936-e937. DOI: 10.1016/s2666-1683(20)33204-3.
• 836 Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC scoreMaresma M, Marchioni M, Campi R, Minervini A, Kriegmair M, Heck M, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Derweesh I, Ghali F, Autorino R, Veccia A, Roussel E, Albertsen M, Pavan N, Antonellia A, Palumbo C, Capitanio U, Klatte T, Erdem S, Rubio-Briones J, Group Y. 836 Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score. European Urology Open Science 2020, 19: e1266-e1267. DOI: 10.1016/s2666-1683(20)33434-0.
• 840 Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registryCampi R, Marchioni M, Roussel E, Capitanio U, Klatte T, Kriegmair M, Erdem S, Rubio-Briones J, Minervini A, Heck M, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Derweesh I, Autorino R, Pavan N, Antonelli A, Palumbo C, Guruli G, Ghali F, Amiel T, Mir M, Group Y. 840 Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry. European Urology Open Science 2020, 19: e1274-e1275. DOI: 10.1016/s2666-1683(20)33438-8.
• 842 Proposal for a two-tier re-classification of stage IV/M1 renal cell carcinoma into M1 (oligometastatic) and M2 (polymetastatic) sub stagesMeagher M, Mir M, Rubio J, Campi R, Minervini A, Mari A, Kriegmair M, Heck M, Amiel T, Van Bruwaene S, Porpiglia F, Checcucci E, Linares E, Hevia V, Musquera M, Bradshaw A, Ghali F, Patel D, Autorino R, Rousel E, Pavan N, Antonelli A, Marchioni M, McKay R, Derweesh I. 842 Proposal for a two-tier re-classification of stage IV/M1 renal cell carcinoma into M1 (oligometastatic) and M2 (polymetastatic) sub stages. European Urology Open Science 2020, 19: e1278-e1279. DOI: 10.1016/s2666-1683(20)33440-6.
• 845 The impact of metastasis location on overall survival among patients with renal cell carcinomaPatel D, Ghali F, Dutt R, Meagher M, Keiner C, Miller N, Murphy J, Derweesh I. 845 The impact of metastasis location on overall survival among patients with renal cell carcinoma. European Urology Open Science 2020, 19: e1284. DOI: 10.1016/s2666-1683(20)33443-1.
• 846 Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registryMeagher M, Mir M, Rubio J, Campi R, Minervini A, Kriegmair M, Heck M, Van Bruwaene S, Linares E, Hevia V, Musquera M, D’anna M, Ghali F, Patel D, Bradshaw A, Autorino R, Guruli G, Rousel E, Albertsen M, Pavan N, Claps F, Antonelli A, Palumbo C, Marchioni M, Derweesh I. 846 Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry. European Urology Open Science 2020, 19: e1285-e1286. DOI: 10.1016/s2666-1683(20)33444-3.
• PT161 Oncologic outcomes after robot-assisted partial nephrectomy in the IRON study: Results from a large, global, multicentric analysis of patients with clinically localized kidney cancerLarcher A, Rosiello G, Minervini A, Mari A, Bensalah K, Khene Z, Schiavina R, Bianchi L, Brunocilla E, Mottrie A, De Naeyer G, Antonelli A, Furlan M, Simeone C, Rha K, Almujalhem A, Derweesh I, Bradshaw A, Ghali F, Kaouk J, Sawczyn G, Bertolo R, Capitanio U, Montorsi F. PT161 Oncologic outcomes after robot-assisted partial nephrectomy in the IRON study: Results from a large, global, multicentric analysis of patients with clinically localized kidney cancer. European Urology Open Science 2020, 19: e1929-e1930. DOI: 10.1016/s2666-1683(20)33900-8.
• PT163 Multicenter comparison of outcomes for clinical and pathologic T3a renal cell carcinomaBradshaw A, Uzzo R, Capitanio U, Lane B, Patil D, Saito K, Ghali F, Kutikov A, Larcher A, Noyes S, Dutt R, Keiner C, Miller N, Wan F, Meagher M, Patel D, Fujii Y, Montorsi F, Master V, Derweesh I. PT163 Multicenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma. European Urology Open Science 2020, 19: e1931-e1932. DOI: 10.1016/s2666-1683(20)33901-x.
• PT169 Impact of change in post surgical serum C-reactive protein on outcomes in renal cell carcrinomaPatel D, Ghali F, Nasseri R, Meagher M, Miller N, Keiner C, Bradshaw A, Patil D, Saito K, Fukushima H, Master V, Fujii Y, Derweesh I. PT169 Impact of change in post surgical serum C-reactive protein on outcomes in renal cell carcrinoma. European Urology Open Science 2020, 19: e1941. DOI: 10.1016/s2666-1683(20)33907-0.
• PT178 Utility and outcomes of lymph node dissection in T2-3 renal cell carcinoma: Analysis of the national cancer databaseGhali F, Patel D, Meagher M, Patel S, Bradshaw A, Dutt R, Miller N, Keiner C, Eldefrawy A, Murphy J, Derweesh I. PT178 Utility and outcomes of lymph node dissection in T2-3 renal cell carcinoma: Analysis of the national cancer database. European Urology Open Science 2020, 19: e1955-e1956. DOI: 10.1016/s2666-1683(20)33916-1.
• Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytomaMeagher M, Lane B, Capitanio U, Mehrazin R, Bradshaw A, Noyes S, Larcher A, Eldefrawy A, Ghali F, Patel D, Bruinius J, Dutt R, Keiner C, Miller N, Wan F, Montorsi F, Derweesh I. Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma. World Journal Of Urology 2020, 39: 1195-1201. PMID: 32556559, DOI: 10.1007/s00345-020-03299-5.
• Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell CarcinomaRoussel E, Campi R, Larcher A, Verbiest A, Antonelli A, Palumbo C, Derweesh I, Ghali F, Bradshaw A, Meagher M, Heck M, Amiel T, Kriegmair M, Rubio J, Musquera M, D’Anna M, Autorino R, Guruli G, Veccia A, Linares-Espinos E, Van Bruwaene S, Hevia V, Porpiglia F, Checcucci E, Minervini A, Mari A, Pavan N, Claps F, Marchioni M, Capitanio U, Beuselinck B, Mir M, Albersen M, Group O. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. European Urology Oncology 2020, 3: 523-529. PMID: 32414697, DOI: 10.1016/j.euo.2020.04.006.
• Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional AnalysisPatel S, Uzzo R, Larcher A, Peyronnet B, Lane B, Pruthi D, Reddy M, Capitanio U, Joshi S, Noyes S, Eldefrawy A, Ghali F, Meagher M, Hamilton Z, Yim K, Nasseri R, Bradshaw A, Dey S, Kirmiz S, Wan F, Liss M, Bensalah K, Montorsi F, Derweesh I. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer 2020, 18: e723-e729. PMID: 32600941, DOI: 10.1016/j.clgc.2020.05.002.
• MP82-16 SFI-UTUC, A NOVEL BASED MORPHOMETRIC SCORING SYSTEM FOR UPPER TRACT UROTHELIAL CELL CARCINOMA: PREDICTING SURVIVAL AND RECURRENCE OUTCOMESPatel* D, Ghali F, Miller N, Patel S, Meagher M, Dutt R, Hamilton Z, Margulis V, Uzzo R, Derweesh I. MP82-16 SFI-UTUC, A NOVEL BASED MORPHOMETRIC SCORING SYSTEM FOR UPPER TRACT UROTHELIAL CELL CARCINOMA: PREDICTING SURVIVAL AND RECURRENCE OUTCOMES. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000974.016.
• PD45-02 EVALUATION OF RENAL CELL CARCINOMA INFLAMMATORY SCORE IN PATIENTS WITH LOCALIZED CLEAR CELL RENAL CELL CARCINOMA: AN INTERNATIONAL, MULTI-INSTITUTIONAL ANALYSISPatil* D, Medline A, Saito K, Lay A, Ghali F, Bilen M, Patel D, Pattaras J, Meagher M, Fukuda S, Yasuda Y, Fujii Y, Ogan K, Derweesh I, Master V. PD45-02 EVALUATION OF RENAL CELL CARCINOMA INFLAMMATORY SCORE IN PATIENTS WITH LOCALIZED CLEAR CELL RENAL CELL CARCINOMA: AN INTERNATIONAL, MULTI-INSTITUTIONAL ANALYSIS. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000932.02.
• Semirigid penile prosthesis: technique and review of literatureGreear G, Ghali F, Hsieh T. Semirigid penile prosthesis: technique and review of literature. Journal Of Visualized Surgery 2020, 6: 17-17. DOI: 10.21037/jovs.2019.11.07.
• PD08-08 TRIFECTA OUTCOMES AFTER PERCUTANEOUS RENAL MASS ABLATION: ANALYSIS OF 234 CASES WITH 3.5 YEARS MEDIAN FOLLOW-UPNandanan* N, Falagario U, Ghali F, Veccia A, Rivera-Sanfeliz G, Eldefrawy A, Reza S, Patel K, Derweesh I, Autorino R. PD08-08 TRIFECTA OUTCOMES AFTER PERCUTANEOUS RENAL MASS ABLATION: ANALYSIS OF 234 CASES WITH 3.5 YEARS MEDIAN FOLLOW-UP. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000835.08.
• PD11-05 MULTICENTER COMPARISON OF OUTCOMES FOR CLINICAL AND PATHOLOGIC T3A RENAL CELL CARCINOMABradshaw* A, Uzzo R, Capitanio U, Lane B, Patil D, Saito K, Ghali F, Kutikov A, Larcher A, Noyes S, Dutt R, Keiner C, Miller N, Wan F, Meagher M, Patel D, Fujii Y, Montorsi F, Master V, Derweesh I. PD11-05 MULTICENTER COMPARISON OF OUTCOMES FOR CLINICAL AND PATHOLOGIC T3A RENAL CELL CARCINOMA. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000845.05.
• PD11-09 ELEVATED C-REACTIVE PROTEIN IS ASSOCIATED WITH POSTOPERATIVE DEVELOPMENT OF PROTEINURIA AND SUBSEQUENT RENAL FUNCTIONAL DECLINE AND MORTALITYMeagher* M, Hamilton Z, Patil D, Saiko K, Bradshaw A, Patel S, Cotta B, Davaro-Comas F, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. PD11-09 ELEVATED C-REACTIVE PROTEIN IS ASSOCIATED WITH POSTOPERATIVE DEVELOPMENT OF PROTEINURIA AND SUBSEQUENT RENAL FUNCTIONAL DECLINE AND MORTALITY. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000845.09.
• MP50-03 IMPACT OF DIABETES MELLITUS ON FUNCTIONAL AND SURVIVAL OUTCOMES IN RENAL CELL CARCINOMADutt* R, Meagher M, Patil D, Saito K, Patel D, Ghali F, Keiner C, Miller N, Bradshaw A, Wan F, Yasuda Y, Fujii Y, Master V, Derweesh I. MP50-03 IMPACT OF DIABETES MELLITUS ON FUNCTIONAL AND SURVIVAL OUTCOMES IN RENAL CELL CARCINOMA. Journal Of Urology 2020, 203: e752. DOI: 10.1097/ju.0000000000000912.03.
• MP50-09 UTILIZATION OF RENAL MASS BIOPSY IN PATIENTS WITH LOCALIZED RENAL CELL CARCINOMAPatel* D, Ghali F, Patel S, Miller N, Bradshaw A, Meagher M, Rivera-Sanfeliz G, Murphy J, Derweesh I. MP50-09 UTILIZATION OF RENAL MASS BIOPSY IN PATIENTS WITH LOCALIZED RENAL CELL CARCINOMA. Journal Of Urology 2020, 203: e755. DOI: 10.1097/ju.0000000000000912.09.
• PD38-07 PROMPT – PROSTATE GENETIC SCORE IMPROVES THE PERFORMANCE OF ESTABLISHED PROSTATE CANCER RISK CALCULATORSGhali* F, Ryan S, Ankerst D, Kattan M, Kader A. PD38-07 PROMPT – PROSTATE GENETIC SCORE IMPROVES THE PERFORMANCE OF ESTABLISHED PROSTATE CANCER RISK CALCULATORS. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000917.07.
• PD49-01 THE IMPACT OF DELAY IN CARE ON RENAL CELL CARCINOMA OUTCOMES: ANALYSIS BASED ON TUMOR SIZEPatel* D, Ghali F, Patel S, Miller N, Bradshaw A, Meagher M, Murphy J, Derweesh I. PD49-01 THE IMPACT OF DELAY IN CARE ON RENAL CELL CARCINOMA OUTCOMES: ANALYSIS BASED ON TUMOR SIZE. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000943.01.
• PD49-05 THE IRON STUDY: INVESTIGATION OF ROBOT-ASSISTED VERSUS OPEN NEPHRON-SPARING SURGERYLarcher* A, Rosiello G, Minervini A, Mari A, Di Maida F, Bensalah K, Peyronnet B, Khene Z, Schiavina R, Bianchi L, Brunocilla E, Mottrie A, De Naeyer G, Mazzone, Aalst, Belgium E, Antonelli A, Furlan M, Simeone C, Rha K, Almujalhem A, Bradshaw A, Ghali F, Kaouk J, Sawczyn G, Bertolo R, Capitanio U, Montorsi F. PD49-05 THE IRON STUDY: INVESTIGATION OF ROBOT-ASSISTED VERSUS OPEN NEPHRON-SPARING SURGERY. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000943.05.
• PD49-09 COMPARATIVE ANALYSIS OF RENAL FUNCTIONAL OUTCOMES OF ACTIVE SURVEILLANCE AND PARTIAL NEPHRECTOMY IN THE MANAGEMENT OF ONCOCYTOMA: AN INTERNATIONAL MULTICENTER ANALYSISMeagher* M, Lane B, Capitanio U, Mehrazin R, Bradshaw A, Noyes S, Lacher A, Eldefrawy A, Ghali F, Keiner C, Dutt R, Miller N, Bruinius J, Patel D, Montorsi F, Derweesh I. PD49-09 COMPARATIVE ANALYSIS OF RENAL FUNCTIONAL OUTCOMES OF ACTIVE SURVEILLANCE AND PARTIAL NEPHRECTOMY IN THE MANAGEMENT OF ONCOCYTOMA: AN INTERNATIONAL MULTICENTER ANALYSIS. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000943.09.
• MP68-16 ONCOLOGIC OUTCOMES AFTER ROBOT-ASSISTED PARTIAL NEPHRECTOMY IN THE IRON STUDY: RESULTS FROM A LARGE, GLOBAL, MULTICENTRIC ANALYSIS OF PATIENTS WITH CLINICALLY LOCALIZED KIDNEY CANCERLarcher* A, Rosiello G, Minervini A, Mari A, Bensalah K, Khene Z, Schiavina R, Bianchi L, Brunocilla E, Mottrie A, De Naeyer G, Antonelli A, Furlan M, Simeone C, Rha K, Almujalhem A, Derweesh I, Bradshaw A, Ghali F, Kaouk J, Sawczyn G, Bertolo R, Capitanio U, Montorsi F. MP68-16 ONCOLOGIC OUTCOMES AFTER ROBOT-ASSISTED PARTIAL NEPHRECTOMY IN THE IRON STUDY: RESULTS FROM A LARGE, GLOBAL, MULTICENTRIC ANALYSIS OF PATIENTS WITH CLINICALLY LOCALIZED KIDNEY CANCER. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000948.016.
• MP68-02 COMPARATIVE ANALYSIS OF FUNCTIONAL OUTCOMES OF OPEN AND MINIMALLY INVASIVE PARTIAL NEPHRECTOMY STRATIFIED BY TUMOR COMPLEXITYGhali* F, Patel D, Patel S, Rha K, Raheem A, Fayez A, Eissa A, Santok G, Tadifa J, Campi R, Minervini A, Sessa F, Alowidah I, Algahtani A, Rumaih A, Jayed M, Arabia S, Micali S, Kriegmair M, Mir M, Raman J, Riepai C, Carrión D, Bazan A, Ballesteros C, Malki M, Autorino R, Veccia A, Capitanio U, Antonelli A, Furlan M, Simeone C, Bada M, Celia D, Illiano E, Costantini E, Mottrie A, Mazzone E, Derweesh I. MP68-02 COMPARATIVE ANALYSIS OF FUNCTIONAL OUTCOMES OF OPEN AND MINIMALLY INVASIVE PARTIAL NEPHRECTOMY STRATIFIED BY TUMOR COMPLEXITY. Journal Of Urology 2020, 203: e1034-e1035. DOI: 10.1097/ju.0000000000000948.02.
• MP68-04 UTILITY AND OUTCOMES OF LYMPH NODE DISSECTION IN T2-3 RENAL CELL CARCINOMAGhali* F, Patel D, Meagher M, Patel S, Bradshaw A, Dutt R, Miller N, Keiner C, Eldefrawy A, Murphy J, Derweesh I. MP68-04 UTILITY AND OUTCOMES OF LYMPH NODE DISSECTION IN T2-3 RENAL CELL CARCINOMA. Journal Of Urology 2020, 203: e1035-e1036. DOI: 10.1097/ju.0000000000000948.04.
• MP68-09 DISPARITIES IN SURVIVAL OUTCOMES IN AFRICAN AMERICANS IN RENAL CELL CARCINOMAMeagher* M, Hamilton Z, Patil D, Saiko K, Bradshaw A, Patel S, Cotta B, Davaro-Comas F, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. MP68-09 DISPARITIES IN SURVIVAL OUTCOMES IN AFRICAN AMERICANS IN RENAL CELL CARCINOMA. Journal Of Urology 2020, 203: e1037-e1038. DOI: 10.1097/ju.0000000000000948.09.
• MP75-11 GENOME-DRIVEN RISK STRATIFICATION IN PROSTATE CANCER IDENTIFIES LOW RISK MENGhali* F, Ryan S, Patel S, Nguyen V, Kader A. MP75-11 GENOME-DRIVEN RISK STRATIFICATION IN PROSTATE CANCER IDENTIFIES LOW RISK MEN. Journal Of Urology 2020, 203: e1145-e1146. DOI: 10.1097/ju.0000000000000961.011.
• Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database.Patel D, Ghali F, Patel S, Miller N, Bradshaw A, Meagher M, Rivera-Sanfeliz G, Murphy J, Derweesh I. Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 662-662. DOI: 10.1200/jco.2020.38.6_suppl.662.
• Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study.Dutt R, Meagher M, Patil D, Saito K, Patel D, Ghali F, Keiner C, Miller N, Bradshaw A, Wan F, Yasuda Y, Fujii Y, Master V, Derweesh I. Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study. Journal Of Clinical Oncology 2020, 38: 666-666. DOI: 10.1200/jco.2020.38.6_suppl.666.
• Does delay in time to surgery impact outcome in renal cell carcinoma: Analysis based on tumor size utilizing the National Cancer Database.Patel D, Ghali F, Meagher M, Bradshaw A, Patel S, Murphy J, Derweesh I. Does delay in time to surgery impact outcome in renal cell carcinoma: Analysis based on tumor size utilizing the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 664-664. DOI: 10.1200/jco.2020.38.6_suppl.664.
• Association of robotic partial nephrectomy for clinical T2a renal mass with improved trifecta outcome compared to open partial nephrectomy: A single surgeon comparative analysis.Ghali F, Elbakry A, Hamilton Z, Nasseri R, Eldefrawy A, Ryan S, Yim K, Patel S, Bradshaw A, Meagher M, Reddy M, Lee H, Derweesh I. Association of robotic partial nephrectomy for clinical T2a renal mass with improved trifecta outcome compared to open partial nephrectomy: A single surgeon comparative analysis. Journal Of Clinical Oncology 2020, 38: 653-653. DOI: 10.1200/jco.2020.38.6_suppl.653.
• Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer.Ghali F, Patel D, Jamieson C, Parsons J, McKay R. Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer. Journal Of Clinical Oncology 2020, 38: 203-203. DOI: 10.1200/jco.2020.38.6_suppl.203.
• Improving detection of higher-risk or locally advanced disease features in stage I and II renal cell carcinoma.Miller N, Derweesh I, Liu M, Bradshaw A, Dutt R, Keiner C, Meagher M, Ghali F, Patel D, Wan F, Shiehmorteza M. Improving detection of higher-risk or locally advanced disease features in stage I and II renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 625-625. DOI: 10.1200/jco.2020.38.6_suppl.625.
• Does pathologic upstaging to PT3A portend a worsened prognosis when compared to non-upstaged PT3A renal cell carcinoma: Analysis of the National Cancer Database.Patel D, Ghali F, Meagher M, Bradshaw A, Patel S, Keiner C, Miller N, Dutt R, Murphy J, Derweesh I. Does pathologic upstaging to PT3A portend a worsened prognosis when compared to non-upstaged PT3A renal cell carcinoma: Analysis of the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 624-624. DOI: 10.1200/jco.2020.38.6_suppl.624.
• The impact of metastasis location on overall survival among patients with renal cell carcinoma.Patel D, Ghali F, Meagher M, Meagher M, Bradshaw A, Patel S, Keiner C, Miller N, Dutt R, Murphy J, Derweesh I. The impact of metastasis location on overall survival among patients with renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 621-621. DOI: 10.1200/jco.2020.38.6_suppl.621.
• Association of De Ritis Ratio and Neutrophil Lymphocyte Ratio with renal functional decline and all-cause mortality in renal cell carcinoma.Keiner C, Meagher M, Patil D, Saito K, Patel D, Ghali F, Dutt R, Miller N, Bradshaw A, Wan F, Yasuda Y, Fuji Y, Master V, Derweesh I. Association of De Ritis Ratio and Neutrophil Lymphocyte Ratio with renal functional decline and all-cause mortality in renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 741-741. DOI: 10.1200/jco.2020.38.6_suppl.741.
• Multicenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma.Bradshaw A, Ghali F, Miller N, Keiner C, Dutt R, Meagher M, Yim K, Patel D, Uzzo R, Lane B, Capitanio U, Derweesh I. Multicenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 758-758. DOI: 10.1200/jco.2020.38.6_suppl.758.
• The role of lymph node dissection in pT2-3 renal cell carcinoma: Analysis of the National Cancer Database.Ghali F, Patel D, Meagher M, Bradshaw A, Patel S, Dutt R, Murphy J, Derweesh I. The role of lymph node dissection in pT2-3 renal cell carcinoma: Analysis of the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 756-756. DOI: 10.1200/jco.2020.38.6_suppl.756.
• Semirigid penile prosthesisGreear G, Ghali F, Hsieh T. Semirigid penile prosthesis. ASVIDE 2020, 7: 37-37. DOI: 10.21037/asvide.2020.037.
• Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging CriteriaHamilton Z, Capitanio U, Pruthi D, Ghali F, Larcher A, Patel D, Eldefrawy A, Patel S, Cotta B, Bradshaw A, Meagher M, Miller N, Carenzi C, Wan F, Liss M, McGregor T, Montorsi F, Derweesh I. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria. Urology 2019, 138: 60-68. PMID: 31836465, DOI: 10.1016/j.urology.2019.11.036.
• Robotic partial nephrectomy for clinical T2a renal mass is associated with improved trifecta outcome compared to open partial nephrectomy: a single surgeon comparative analysisGhali F, Elbakry A, Hamilton Z, Yim K, Nasseri R, Patel S, Eldefrawy A, Ryan S, Bradshaw A, Meagher M, Bree K, Reddy M, Lee H, Derweesh I. Robotic partial nephrectomy for clinical T2a renal mass is associated with improved trifecta outcome compared to open partial nephrectomy: a single surgeon comparative analysis. World Journal Of Urology 2019, 38: 1113-1122. PMID: 31701211, DOI: 10.1007/s00345-019-02994-2.
• Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiologyRoberts J, Ghali F, Aganovic L, Bechis S, Healy K, Rivera-Sanfeliz G, Autorino R, Derweesh I. Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology. Abdominal Radiology 2019, 44: 3893-3905. PMID: 31701194, DOI: 10.1007/s00261-019-02293-9.
• Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell CarcinomaGhali F, Patel S, Derweesh I. Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma. Journal Of Oncology 2019, 2019: 7309205. PMID: 31057615, PMCID: PMC6463563, DOI: 10.1155/2019/7309205.
• MP23-18 A CLINICAL TRACKING PROGRAM FOR URETERAL STENTS INTEGRATED INTO EMRGhali* F, Papagiannopoulos D, Sur R, Bechis S. MP23-18 A CLINICAL TRACKING PROGRAM FOR URETERAL STENTS INTEGRATED INTO EMR. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555623.35797.55.
• MP54-09 PROSTATECTOMY IN MEN WITH CLINICALLY POSITIVE LYMPH NODES: COMPARING SURVIVAL IN HIGH RISK CN-, PATHOLOGICALY NEGATIVE NODES, AND PATHOLOGICALLY POSITIVE NODAL DISEASERyan* S, Ghali F, Hansen M, Hayn M, Sammon J, Sarkar R, Murphy J, Kader A, Rose B. MP54-09 PROSTATECTOMY IN MEN WITH CLINICALLY POSITIVE LYMPH NODES: COMPARING SURVIVAL IN HIGH RISK CN-, PATHOLOGICALY NEGATIVE NODES, AND PATHOLOGICALLY POSITIVE NODAL DISEASE. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000556686.46954.87.
• Prostatectomy in men with clinically positive lymph nodes.Ghali F, Ryan S, Hansen M, Hayn M, Sammon J, Sarkar R, Murphy J, Kader A, Rose B. Prostatectomy in men with clinically positive lymph nodes. Journal Of Clinical Oncology 2019, 37: 327-327. DOI: 10.1200/jco.2019.37.7_suppl.327.
• A novel ex vivo trainer for robotic vesicourethral anastomosisShee K, Koo K, Wu X, Ghali F, Halter R, Hyams E. A novel ex vivo trainer for robotic vesicourethral anastomosis. Journal Of Robotic Surgery 2019, 14: 21-27. PMID: 30689167, DOI: 10.1007/s11701-019-00926-1.
• Changing incidence of factitious renal stone disease.Ghali F, Dagrosa L, Moses R, Ursiny M, Eisner B, Pais V. Changing incidence of factitious renal stone disease. Clinical Nephrology 2018, 90: 102-105. PMID: 29882511, DOI: 10.5414/cn109331.
• Chapter 26 Penile Fibrogenesis Affecting Men’s Reproductive and Sexual Health Role of Age and Environmental FactorsRaheem O, Ghali F, Rajasekaran M. Chapter 26 Penile Fibrogenesis Affecting Men’s Reproductive and Sexual Health Role of Age and Environmental Factors. 2018, 423-437. DOI: 10.1016/b978-0-12-801299-4.00026-8.
• Practice Makes Perfect: Correlations Between Prior Experience in High-level Athletics and Robotic Surgical Performance Do Not Persist After Task RepetitionShee K, Ghali F, Hyams E. Practice Makes Perfect: Correlations Between Prior Experience in High-level Athletics and Robotic Surgical Performance Do Not Persist After Task Repetition. Journal Of Surgical Education 2017, 74: 630-637. PMID: 28087244, DOI: 10.1016/j.jsurg.2016.12.008.
• Does Travel Time to a Radiation Facility Impact Patient Decision‐Making Regarding Treatment for Prostate Cancer? A Study of the New Hampshire State Cancer RegistryGhali F, Celaya M, Laviolette M, Ingimarsson J, Carlos H, Rees J, Hyams E. Does Travel Time to a Radiation Facility Impact Patient Decision‐Making Regarding Treatment for Prostate Cancer? A Study of the New Hampshire State Cancer Registry. The Journal Of Rural Health 2016, 34: s84-s90. PMID: 27862285, DOI: 10.1111/jrh.12224.
• What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution’s experienceGhali F, Moses R, Raffin E, Hyams E. What factors are associated with unplanned return following transurethral resection of bladder tumor? An analysis of a large single institution’s experience. Scandinavian Journal Of Urology 2016, 50: 370-373. PMID: 27438524, DOI: 10.1080/21681805.2016.1201856.
• MP11-09 PRIOR EXPERIENCE IN ATHLETICS IS SIGNIFICANTLY ASSOCIATED WITH INCREASED ROBOTIC SURGICAL SKILL IN ROBOT-NAIVE MEDICAL STUDENTSShee K, Ghali F, Hyams E. MP11-09 PRIOR EXPERIENCE IN ATHLETICS IS SIGNIFICANTLY ASSOCIATED WITH INCREASED ROBOTIC SURGICAL SKILL IN ROBOT-NAIVE MEDICAL STUDENTS. Journal Of Urology 2016, 195: e114-e115. DOI: 10.1016/j.juro.2016.02.2380.
• Renal Papillary Necrosis Appearing as Bladder Cancer on ImagingDagrosa L, Ghali F, Gormley E. Renal Papillary Necrosis Appearing as Bladder Cancer on Imaging. Journal Of Endourology Case Reports 2016, 2: 27-29. PMID: 27579408, PMCID: PMC4996587, DOI: 10.1089/cren.2016.0011.
• Keratinized squamous metaplasia of the upper urinary tract resulting in recurrent renal colic.Ghali F, Pattison E, Pais V. Keratinized squamous metaplasia of the upper urinary tract resulting in recurrent renal colic. Clinical Nephrology 2015, 84: 251-3. PMID: 26249552, DOI: 10.5414/cn108581.
• Unplanned Hospital Return for Infection following Ureteroscopy—Can We Identify Modifiable Risk Factors?Moses R, Ghali F, Pais V, Hyams E. Unplanned Hospital Return for Infection following Ureteroscopy—Can We Identify Modifiable Risk Factors? Journal Of Urology 2015, 195: 931-936. PMID: 26410731, DOI: 10.1016/j.juro.2015.09.074.
• Heterotopic Pancreatic Tail Appearing as Adrenal Mass in a Patient With Left Pelvic KidneyGhali F, Hyams E. Heterotopic Pancreatic Tail Appearing as Adrenal Mass in a Patient With Left Pelvic Kidney. Urology 2015, 85: e37-e38. PMID: 25917743, DOI: 10.1016/j.urology.2015.01.037.